Candel Therapeutics CEO: Putting patients first is the key to reframing cancer treatment

In the biopharmaceutical world, where innovation and breakthroughs often dominate headlines, a fundamental question is frequently overlooked: are we truly listening to patients? For Paul Peter Tak CEO of Candel Therapeutics Inc (NASDAQ:CADL), the answer has shaped a career rooted in both scientific discovery and personal resilience. As Candel prepares to unveil pivotal data from its prostate cancer clinical trials, Dr Tak reflects on the crucial role of embedding patient voices in the heart of medical innov ...